🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

287 results for “Ono” Clear

  1. Salbutamol Aldo-Unión 100 microgramos/dosis suspensión para inhalación en envase a presión, Inhalation powder with lactose monohydrate and magnesium stearate, BREO ELLIPTA, Fluticasone furoate and Vilanterol inhalation powder 100 mcg/25 mcg

    Sandoz Pty Ltd

    Asthma

    phase 3 small molecule active

    1 trial

  2. Seasonale (levonorgestrel and ethinyl estradiol)

    Teva Pharma GmbH

    Osteopenia

    phase 3 small molecule terminated

    1 trial

  3. Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]

    Teva Pharma GmbH

    Healthy

    phase 3 small molecule completed

    1 trial

  4. Spironolactone

    Takeda

    Atrial Fibrillation

    phase 3 small molecule active

    1 trial

  5. Start antiplatelet monotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule completed

    1 trial

  6. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  7. Temomedac 20 mg hard capsules, Temomedac 5 mg hard capsules, Tirabrutinib, Temomedac 100 mg hard capsules, Truxima 500 mg concentrate for solution for infusion, Truxima 100 mg concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Relapsed/refractory primary central nervous system lymphoma

    phase 3 small molecule active

    1 trial

  8. The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.

    Lacuna Pharma Pty Ltd

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  9. The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα

    Lacuna Pharma Pty Ltd

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

  10. Tiratricol

    Ultragenyx UK Limited

    Monocarboxylate Transporter 8 Deficiency

    phase 3 small molecule completed

    1 trial

  11. Tiratricol, Matching placebo (for participants allocated to the placebo group in the Randomized Treatment Period)

    Rare Thyroid Therapeutics International AB

    Monocarboxylate Transporter 8 (MCT8) deficiency

    phase 3 small molecule active

    1 trial

  12. VINCRISTINE SULFATE, RITUXIMAB, RITUXIMAB, APIXABAN, Golcadomide, PREDNISONE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE MONOHYDRATE, Golcadomide, Golcadomide 0.2 mg capsule, Golcadomide 0.3 mg capsule, Golcadomide 0.4 mg capsule, Golcadomide, Neulasta 6 mg solution for injection, PREDNISOLONE , VINCRISTINE SULFATE

    Celgene Europe Limited

    High-risk Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  13. Vonoprazan

    Phathom Pharmaceuticals

    Erosive Esophagitis

    phase 3 small molecule completed

    2 trials

  14. Vonoprazan

    Phathom Pharmaceuticals

    Non-Erosive Gastro-Esophageal Reflux Disease

    phase 3 small molecule completed

    2 trials

  15. Vonoprazan

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    1 trial

  16. Vonoprazan

    Takeda

    Helicobacter Pylori

    phase 3 small molecule completed

    1 trial

  17. Vonoprazan

    Phathom Pharmaceuticals

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  18. Xevinapant (Debio 1143)

    Serono Europe Limited

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

  19. donor lymphocyte infusion

    The First People's Hospital of Lianyungang

    Minimal Residual Disease

    phase 3 mab completed

    1 trial

  20. iron isomaltoside(Monofer®)

    Hospital Authority, Hong Kong

    Anemia, Iron-Deficiency

    phase 3 small molecule completed

    1 trial

  21. lactose monohydrate - 100,00 mg/tablet cellulose microcrystalline - 95,60 mg/tablet Croscarmellose sodium - 2,00 mg/tablet Magnesium stearate - 2,40 mg/tablet table coating - OPADRY 20A82938 Yellow - COLORCON, Asmenol, 10 mg, tabletki powlekane

    COLLEGIUM PHARMACEUTICAL, INC

    Ischemia of the lower limbs in the course of obstructive artery disease

    phase 3 small molecule active

    1 trial

  22. levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets

    Teva Pharma GmbH

    Dysmenorrhea

    phase 3 small molecule completed

    2 trials

  23. metronomic adjuvant chemotherapy with capecitabine

    Chongqing Claruvis Pharmaceutical Co.,

    Nasopharyngeal Cancinoma (NPC)

    phase 3 small molecule active

    1 trial

  24. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources